KORU MEDICAL SYSTEMS INC

Company Overview

KORU Medical Systems Inc. is a Healthcare company in the Medical Instruments & Supplies industry that develops and commercializes large-volume subcutaneous infusion systems, led by its FREEDOM Infusion Systems. Its products are used mainly for home-based and alternate-site delivery of therapies such as SCIg for PIDD and CIDP, with growing use in other subcutaneous drug applications and selected intravenous antibiotic administration. Recent filings show strong revenue growth driven by core consumables and pump volumes, especially internationally, alongside ongoing pharma partner services and clinical trial supply work. The business depends on a concentrated distributor network, regulatory clearances, reimbursement support, and reliable manufacturing and supply-chain execution.

Executive Compensation Practices

Executive pay at KORU is likely tied closely to revenue growth, gross margin performance, and progress on international expansion and new product adoption, which are the key operating drivers highlighted in the filings. The company’s 2025 results suggest bonus and incentive outcomes may reflect top-line expansion, narrower losses, and operating leverage, even as margin pressure from tariffs, manufacturing costs, and mix shifts remains relevant. The MD&A specifically notes higher SG&A from compensation and bonus accruals, commissions, and legal fees, indicating that pay and sales incentives are a meaningful part of operating expenses. For a medical device company with a small workforce and heavy reliance on product commercialization, executives may also be rewarded for regulatory milestones, customer wins, supply-chain stability, and execution of manufacturing scale-up.

Insider Trading Considerations

Insider trading patterns in KORU may be influenced by milestone-driven revenue timing, distributor inventory swings, and international shipment cadence, all of which can create short-term variability in reported results. Because the company relies on a small number of distributors and several single-source suppliers, insiders may be especially sensitive to information about customer concentration, product demand, supply disruptions, and margin changes from tariffs or manufacturing costs. As a Medical Instruments & Supplies company, trading activity may also cluster around FDA clearances, reimbursement developments, new therapy launches, and updates on adoption in SCIg and other subcutaneous drug markets. Researchers should watch for purchases or sales around quarters with unusually strong international shipments, margin shifts, or financing discussions, since those events can materially affect sentiment and valuation.